We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy...